This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Exonate to present data on lead candidate EXN407 at ARVO 2019, the internationally recognised vision and ophthalmology conference

9 April 2019 - 30 October 2019

Exonate to present data on lead candidate EXN407 at ARVO 2019, the internationally recognised vision and ophthalmology conference

Cambridge, UK – 25 March 2019: Exonate, an early stage biotechnology company, is pleased to announce that Dr Jennifer Batson will be presenting data at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, taking place in Vancouver from 28 April – 2 May 2019.

The poster presentation will outline preclinical data on Exonate’s lead candidate, EXN407, a specific SRPK1 inhibitor with high retinal bioavailability for the treatment of diabetic macular oedema.

Abstract Title: EXN407, a novel topical therapeutic candidate with high retinal bioavailability for the treatment of diabetic macular oedema (DMO), inhibits ocular neovascularisation

Session: 104

Date and Time: Sunday 28 April 2019 at 08:00-09:45 AM and 17:00-18:00 PT

Posterboard Number: 26 – A0100

Additionally, Prof. David Bates will be giving an oral presentation on the design of compounds with the physicochemical properties required for eye drop delivery in large eyes, using ex vivo permeability modelling.

Abstract Title: Designing topical VEGF-A inhibitors with high retinal bioavailability using ex vivo permeability modelling

Session: 340

Date and Time: Tuesday 30 April 2019 at 12.00-12.15 PT

Location: Room East 2/3

Exonate’s strategy is to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DMO), by using mRNA targeted therapies. Exonate has developed small molecules that inhibit the production of pro-angiogenic VEGF through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing.

Catherine Beech, CEO and members of Exonate’s management team will be available for meetings whilst there and contact can be made via Sarah Buchallet.


Exonate Limited

Sarah Buchallet, Marketing

Catherine Beech, CEO
Tel:  +44 (0) 1223 437042

FTI Consulting
Tel:  +44 (0) 20 3727 1000
Natalie Garland-Collins / Lucy McKeone

About Exonate:

Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of the retina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older.  The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specialising in the biology and biochemical pathways of VEGF splice variants.

Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing.  These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD.  Through a Wellcome Trust funded project, Exonate will complete an optimisation programme to nominate a pre-clinical candidate drug with optimal characteristics ahead of regulatory toxicology and safety pharmacology studies which will support an application to the regulatory authorities for clinical evaluation.  Exonate expects to reach this milestone and enter the clinic in early 2020.

Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies.

About Diabetic Macular Oedema (DMO)*:

DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognising faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease.

About wet Age-Related Macular Degeneration (wet AMD):

Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset.

The main currently available treatment options for DMO and wet AMD are:

·         anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew.

·         Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss.

·         With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO.


Please contact Sarah Buchallet at Exonate for further information 01223 437042